Published 2019
| Version v1
Publication
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
- Creators
- Folschweiller, Nicolas
- Behre, Ulrich
- Dionne, Marc
- Durando, Paolo
- Esposito, Susanna
- Ferguson, Linda
- Ferguson, Murdo
- Hillemanns, Peter
- McNeil, Shelly A
- Peters, Klaus
- Ramjattan, Brian
- Schwarz, Tino F
- Supparatpinyo, Khuanchai
- Suryakirian, Pemmaraju V
- Janssens, Michel
- Moris, Philippe
- Decreux, Annabelle
- Poncelet, Sylviane
- Struyf, Frank
- Others:
- Folschweiller, Nicola
- Behre, Ulrich
- Dionne, Marc
- Durando, Paolo
- Esposito, Susanna
- Ferguson, Linda
- Ferguson, Murdo
- Hillemanns, Peter
- Mcneil, Shelly A
- Peters, Klau
- Ramjattan, Brian
- Schwarz, Tino F
- Supparatpinyo, Khuanchai
- Suryakirian, Pemmaraju V
- Janssens, Michel
- Moris, Philippe
- Decreux, Annabelle
- Poncelet, Sylviane
- Struyf, Frank
Description
This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.
Additional details
- URL
- http://hdl.handle.net/11567/957678
- URN
- urn:oai:iris.unige.it:11567/957678
- Origin repository
- UNIGE